Table 3.
Summary of studies of CU programs.
| Study | Patients | Prior ETa | Combination therapy | PFS, median (95% CI) |
|---|---|---|---|---|
| Ban et al., 2018 [26] | 24 | 3 (0–4) | PA + AI | 4.8 |
| Battisti et al., 2019 [25] | 118 | 1-2, 42.4% 3-5, 54.2% 6-7, 1.7% |
PA + AI, 48.3% PA + FU, 47.5% PA + TA, 4.2% |
4.5 (3.7–5.9) |
| Demir et al., 2020 [29] | 43 | ≥3 | PA + TA, 44.1% PA + LE, 13.9% PA + AN, 6.9% |
7 (4–10) |
| Du Rusquec et al., 2018 [27] | 60 | 3 (1–7) | PA + FU | 5.8 (3.9–7.3) |
| Herrscher et al., 2020 [28] | 77 | 2 | PA + FU | 7.6 (4.6–10.4) |
| Hoste et al., 2018 [24] | 82 | 4 (1–7) | PA + LE, 89.0% PA + FU = 3.7% PA + other, 7.2% |
3.1 (2.7–4.7) |
| Maurer et al., 2018 [23] | 34 | 3 (1–6) | PA + LE, 44.1% PA + FU, 23.5% PA + AN, 20.6% PA + other, 11.8% |
3.1 (2.5–5.5) |
| PALBOCOMP | 219 | 3 (2–3) | PA + AI, 50.2% PA + FU, 39.7% PA + TA, 3.6% |
6.0 (5.7–7.0) |
Abbreviations: AI = aromatic inhibitors; AN = anastrazole; CU = compassionate use; ET = endocrine therapy; FU = fulvestrant; ET = endocrine therapy; LE = letrozole; PA = palbociclib; PFS = progression free survival; TA = tamoxifen.
a
Median (range) unless specified.